Core Insights - Preliminary unaudited consolidated accounts for Vow ASA for Q3 2025 indicate lower-than-expected EBITDA due to underestimated costs in two key projects within the Industrial segment [1] - Positive developments continue in the Maritime and Aftersales segments, driven by strong demand and increased margins [1] - A profit improvement program has been launched to enhance cost control, profitability, and operational efficiency [2] Financial Performance - Preliminary EBITDA for the Industrial Solutions segment is approximately NOK -70 million, while total EBITDA for the Group is approximately NOK -33 million for Q3 2025 [1] - The reversal of revenue in Q3 2025 has no cash impact, but it affects project margins and technical reporting [1] Strategic Initiatives - The company is in close cooperation with customers to complete the two major projects, which are in their final stages [1] - A revisit of Vow's strategies has commenced as part of the ongoing efforts to improve profitability [2] Upcoming Reports - The final Q3 2025 report with more details is scheduled for release on 19 November 2025 at 07:00 CET [3] Company Overview - Vow ASA and its subsidiaries focus on preventing pollution by converting biomass and waste into valuable resources and clean energy [5] - The company is a leader in wastewater purification and offers solutions for industries transitioning towards a fossil-free future [7][8]

Core Insights - Sanofi's high-dose influenza vaccine, Efluelda (Fluzone High-Dose in North America), shows significantly reduced hospitalization risk for adults aged 65 and older compared to standard-dose vaccines, as evidenced by the FLUNITY-HD study [1][4][3] Study Design and Results - The FLUNITY-HD study is the largest of its kind, involving nearly half a million participants across multiple seasons and geographic areas, demonstrating the effectiveness of the high-dose vaccine [4][6] - The study found a 31.9% additional reduction in laboratory-confirmed influenza hospitalizations for older adults receiving the high-dose vaccine compared to standard-dose [4][7] - Additional findings include an 8.8% reduction in pneumonia/influenza hospitalizations and a 6.3% reduction in hospitalizations due to cardio-respiratory events [4][7] Public Health Implications - The high-dose vaccine could prevent one all-cause hospitalization for every 515 older adults vaccinated, highlighting its potential to improve quality of life for vulnerable seniors and reduce healthcare costs [3][4] - The results may influence public health strategies and clinical guidelines, reinforcing the importance of high-dose vaccines for older adults [2][3] Product Information - Efluelda is specifically designed for adults aged 60 and older in Europe and for those aged 65 and older in North America, providing four times the antigen compared to standard-dose vaccines [8][9] - The vaccine aims to enhance immune response in older adults, who are at a higher risk for severe influenza-related illnesses [9]

Core Insights - FORVIA reported third-quarter 2025 sales of €6.12 billion, stable on an organic basis, but down 3.7% year-over-year due to negative currency effects [1][8][24] - The company confirmed its full-year 2025 guidance, maintaining targets for sales, operating margin, net cash flow, and leverage [3][25][29] Financial Performance - Consolidated sales in Q3 2025 were impacted by a €238 million negative currency effect, primarily from the euro's depreciation against the USD and RMB [8][24] - Organic growth in product sales was 1.1%, with solid growth in Electronics, Clean Mobility, and Lifecycle Solutions [7][10][11] - The company experienced a 440 basis points underperformance compared to global automotive production, which grew by 4.4% [8][15] Segment Analysis - **Seating**: Reported a decline of 12.7% in sales, affected by an unfavorable customer mix in China [9][11] - **Electronics**: Achieved a 14.3% increase in sales, driven by strong demand for radars and battery management systems [9][11] - **Interiors**: Experienced a slight decline in organic sales, primarily due to normalization of tooling sales [12] - **Clean Mobility**: Recorded strong growth, particularly in North America, benefiting from electrification trends [13] - **Lifecycle Solutions**: Returned to growth after five quarters of decline, driven by commercial vehicle business [13] Regional Performance - **EMEA**: Sales decreased by 2.5% on an organic basis, impacted by production shutdowns and market slowdowns [16][17] - **North America**: Organic sales advanced by 5.8%, driven by growth with US and Japanese car manufacturers [18] - **Asia**: Organic sales declined by 2.7%, with China down 7.4% due to an unfavorable customer mix [18][19] Strategic Initiatives - The company is focused on cost reduction and financial discipline through its EU-FORWARD initiative, which includes job reductions and a global SIMPLIFY program aimed at reducing costs by €110 million by 2028 [21][22] - FORVIA successfully raised approximately €1.3 billion in new financing to refinance short-term obligations and enhance its financial profile [23][24]

The new ranking comes as Rachel Reeves is preparing for her Budget - Hannah McKay/Reuters Britain has tumbled down the global rankings of personal tax competitiveness in the wake of Rachel Reeves’s £25bn raid on employers last year. The UK has dropped five places to 25th in the rankings of 38 OECD nations in just a year, according to the Centre for Policy Studies (CPS). The Chancellor’s levy on National Insurance contributions paid by employers, widely considered a jobs tax, combined with the increase i ...

Core Viewpoint - Roche's Gazyva®/Gazyvaro® (obinutuzumab) has received FDA approval for treating adult patients with active lupus nephritis, offering a new standard of care with a shorter infusion time and improved treatment regimen [1][2]. Company Overview - Roche is a leading biotechnology company founded in 1896, focusing on developing innovative medicines and diagnostics to improve global health [8]. - The company has a strong commitment to sustainability and aims to achieve net zero by 2045 [9]. Product Details - Gazyva/Gazyvaro is a Type II engineered humanized monoclonal antibody targeting CD20, designed to deplete disease-causing B cells in lupus nephritis, potentially preventing kidney damage [4][5]. - The drug is already approved in 100 countries for various hematological cancers and is part of a collaboration between Genentech and Biogen in the U.S. [4]. Clinical Study Insights - The FDA approval is based on positive results from the phase II NOBILITY and phase III REGENCY studies, where 46.4% of participants on Gazyva/Gazyvaro achieved a complete renal response compared to 33.1% on standard therapy alone [2][5]. - The REGENCY study involved 271 participants and demonstrated the efficacy and safety of Gazyva/Gazyvaro in combination with standard therapy [6]. Market Impact - Lupus nephritis affects over 1.7 million people globally, predominantly impacting women of color and those of childbearing age, with untreated cases leading to significant health risks [2][7]. - The approval of Gazyva/Gazyvaro provides a new treatment option that could prevent long-term complications, including kidney failure, thus addressing a critical need in the market [2][5].

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 13 October up to and including 17 October 2025 a total of 29.981 shares were repurchased at an average price of €16.6672 for a total amount of €499,698.04 To date, the total consideration for shares repurchased amounts to €5,024,854.16 representing 50.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the ...

Core Viewpoint - Roche's Gazyva®/Gazyvaro® (obinutuzumab) has received FDA approval for treating adult patients with active lupus nephritis, offering a new standard of care with a shorter infusion time and improved treatment regimen [1][2]. Group 1: FDA Approval and Treatment Efficacy - The FDA approved Gazyva/Gazyvaro for adult patients with active lupus nephritis who are on standard therapy, allowing for a 90-minute infusion after the first dose [1]. - In the phase III REGENCY study, 46.4% of participants receiving Gazyva/Gazyvaro achieved a complete renal response compared to 33.1% on standard therapy alone, indicating significant efficacy [2][8]. - The approval is based on positive results from both phase II NOBILITY and phase III REGENCY studies, demonstrating the drug's superiority over standard therapy [8]. Group 2: Patient Impact and Disease Background - Lupus nephritis affects over 1.7 million people globally, predominantly impacting women of color and those of childbearing age, with untreated cases leading to a one-third progression to end-stage kidney disease [3][11]. - The approval of Gazyva/Gazyvaro is seen as a significant advancement in providing hope for patients suffering from chronic pain and the fear of worsening kidney health [2][3]. Group 3: Future Prospects and Pipeline - Gazyva/Gazyvaro is also being investigated for other conditions, including systemic lupus erythematosus and various kidney-related diseases, indicating a broad pipeline for Roche in this therapeutic area [5][6]. - The European Medicines Agency has issued a positive opinion for Gazyva/Gazyvaro, with a final decision expected soon, suggesting potential for further market expansion [4].

Core Insights - TGS has secured an OBN acquisition contract in the Gulf of America, with a 4D monitor survey set to begin in Q4 2025 and lasting approximately 4.5 months [1][2] Company Overview - TGS is a leading provider of energy data and intelligence, offering advanced technology and solutions across the entire energy value chain [3] - The company has a diverse energy data library and aims to support clients in making informed decisions regarding energy resource exploration and production [3] Market Position - The Gulf of America is identified as a core market for TGS's OBN business, highlighting the importance of this region for the company's operations [2] - The contract is with a repeat IOC customer, indicating a strong relationship and trust in TGS's capabilities [2]

Over the weekend, Emirates NBD Bank PJSC said it plans to invest $3 billion in The exuberance to what’s happening elsewhere is striking. Recent US collapses of Tricolor Holdings and First Brands Group have stoked fears of hidden credit losses. India itself is trying to work things out with the US after it was slapped with 50% tariffs that could hit its growth. Live Events“The success story of foreign banks acquiring Indian banks is very limited” and hasn’t always reflected in profit and revenue growth, sai ...

I am positive on Figure Technology Solutions (NASDAQ: FIGR ), as I believe it has a solid tech and regulatory moat that enables it to sustainably win share in the markets it competes in. To be specific, FIGRI'm a passionate investor with a strong foundation in fundamental analysis and a keen eye for identifying undervalued companies with long-term growth potential. My investment approach is a blend of value investing principles and a focus on long-term growth. I believe in buying quality companies at a disc ...